CRG-150 is entering first-in-human testing as an unconventional immunotherapy for patients with relapsed or refra9ctory metastatic prostate cancer and other solid tumors. The autologous, CRISPR-edited cell therapy targets steroid receptor coactivator 3, or SRC-3, in regulatory T cells. Tregs help maintain immune tolerance but can suppress antitumor immunity in prostate cancer. By disrupting SRC-3, CRG-150 […]
SCD1 is an enzyme that helps prostate-cancer cells convert saturated fatty acids into monounsaturated fatty acids, which support cell membranes, energy storage and survival signaling. Functional research suggests that some tumors rely on SCD1 activity. Blocking this pathway can disrupt lipid synthesis, androgen-receptor signaling and survival pathways such as AKT. This provides the rationale for […]
Fifteen years after sipuleucel‑T became the first cellular immunotherapy to show an overall‑survival benefit in metastatic castration‑resistant prostate cancer (mCRPC), a new phase Ib trial at Washington University is testing whether adding the IL‑15 superagonist N‑803 (Anktiva) can turn that modest, durable survival signal into a stronger, more consistent immune attack on metastatic disease. The […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Research really took a holiday this past week! But I did find something interesting for a short read. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can […]
A decade after diagnosis, most men with localized prostate cancer are far more likely to die of something else than of their cancer, regardless of whether they choose surgery, radiation, or active surveillance. This is the central message of the long-term follow-up from the CEASAR study, a large, prospective, observational population-based U.S. cohort that enrolled […]
Bipolar androgen therapy (BAT) is a paradoxical treatment strategy for metastatic androgen pathway modulation–resistant prostate cancer (mAPMR), formerly known as metastatic castration‑resistant prostate cancer (mCRPC), that replaces continuous androgen suppression with cyclical, supraphysiologic testosterone exposure, aiming to exploit the tumor’s dependence on an overactive androgen receptor (AR). The approach was pioneered by Samuel Denmeade and […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Research seems to have slowed down for August, but what we have this week is really good. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find […]
Bria-PROS+ has received clearance from the U.S. Food and Drug Administration to enter clinical testing as an investigational personalized, off-the-shelf cellular immunotherapy for prostate cancer. The FDA completed its review of the Investigational New Drug application allowing a Phase 1/2a clinical study to move forward. The study is expected to evaluate the safety, tolerability, and […]
A small but encouraging clinical dataset suggests that 67Cu-SAR-bisPSMA may produce substantial anti-tumour activity in patients with metastatic castration-resistant prostate cancer (mCRPC) who have exhausted multiple treatment options. The findings come from the SECuRE clinical trial, in which 19 participants received treatment with 67Cu-SAR-bisPSMA at an 8 GBq dose. Despite the advanced disease setting, treatment […]
A landmark 2026 study in Clinical Cancer Research reframes surface-target therapy in advanced prostate cancer by placing B7-H3 (CD276) at the center of a continuum-wide strategy. Integrating the JHU-PANORAMA single-cell atlas (~1M cells, 213 patients) with patient-derived xenografts, metastatic rapid-autopsy tissues, and mechanistic cell-line work, the authors show that B7-H3 is the most uniformly expressed […]